The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus
Open accessThe DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Individuals with type 1 diabetes mellitus are at high risk for the development of hypertension, contributing to cardiovascular complications. Hyperglycaemia-mediated neurohormonal activation increases arterial stiffness, and is an important contributing factor for hypertension. Since the sodium glucose cotransport-2 (SGLT2) inhibitor empagliflozin lowers blood pressure and HbA1c in type 1 diabetes mellitus, we hypothesized that this agent would also reduce arterial stiffness and markers of sympathetic nervous system activity. METHODS: Blood pressure, arterial stiffness, heart rate variability (HRV) and circulating adrenergic mediators were measured during clamped euglycaemia (blood glucose 4-6 mmol/L) and hyperglycaemia (blood glucose 9-11 mmol/L) in 40 normotensive type 1 diabetes mellitus patients. Studies were repeated after 8 weeks of empagliflozin (25 mg once daily). RESULTS: In response to empagliflozin during clamped euglycaemia, systolic blood pressure (111 ± 9 to 109 ± 9 mmHg, p = 0.02) and augmentation indices at the radial (-52% ± 16 to -57% ± 17, p = 0.0001), carotid (+1.3 ± 1 7.0 to -5.7 ± 17.0%, p < 0.0001) and aortic positions (+0.1 ± 13.4 to -6.2 ± 14.3%, p < 0.0001) declined. Similar effects on arterial stiffness were observed during clamped hyperglycaemia without changing blood pressure under this condition. Carotid-radial pulse wave velocity decreased significantly under both glycemic conditions (p ≤ 0.0001), while declines in carotid-femoral pulse wave velocity were only significant during clamped hyperglycaemia (5.7 ± 1.1 to 5.2 ± 0.9 m/s, p = 0.0017). HRV, plasma noradrenalin and adrenaline remained unchanged under both clamped euglycemic and hyperglycemic conditions. CONCLUSIONS: Empagliflozin is associated with a decline in arterial stiffness in young type 1 diabetes mellitus subjects. The underlying mechanisms may relate to pleiotropic actions of SGLT2 inhibition, including glucose lowering, antihypertensive and weight reduction effects. CLINICAL TRIAL REGISTRATION: NCT01392560.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Regardless of the underlying mechanisms, relatively modest reductions in BP with SGLT2 inhibition are unlikely to fully explain the substantial risk reductions in kidney failure and cardiovascular outcomes with these agents, 9,[35][36][37] a conclusion supported by the finding that less than 10% of treatment effects on kidney and cardiovascular outcomes were explained by change in systolic BP.”
From Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial (2021) · cites this paper as [36]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Adler, A. I. (2000) · BMJ · doi:10.1136/bmj.321.7258.412 · Cited by 2,133 · cited 1×
“Figure 1 Physiological mechanisms implicated in arterial stiffness low lowering strategies also increase the risk of severe hypoglycemic events [15-17] and promote weight gain and sodium retention resulting in higher blood pressure [16-18], thereby mitigating the benefit that can be achieved through tight glycemic con…”
Mann, J. F., Schmieder, R. E., McQueen, M., Dyal, L., Schumacher, H., Pogue, J., Wang, X., Maggioni, A., Budaj, A., Chaithiraphan, S., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61236-2 · Cited by 1,589 · cited 1×
“Unfortunately, blockade of RAAS pathways provides incomplete protection against the development of diabetic complications [6] and dual RAAS blockade strategies may increase the risk of serious adverse effects such as acute kidney injury and hyperkalemia [7,8].”
Severe hypoglycemia and risks of vascular events and death
Zoungas, S., Patel, A., Chalmers, J., de Galan, B. E., Li, Q., Billot, L., Woodward, M., Ninomiya, T., Neal, B., MacMahon, S., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003795 · Cited by 1,471 · cited 1×
“Figure 1 Physiological mechanisms implicated in arterial stiffness low lowering strategies also increase the risk of severe hypoglycemic events [15-17] and promote weight gain and sodium retention resulting in higher blood pressure [16-18], thereby mitigating the benefit that can be achieved through tight glycemic con…”
Cherney, D. Z. I., Perkins, B. A., Soleymanlou, N., Maione, M., Lai, V., Lee, A., Fagan, N. M., Woerle, H. J., Johansen, O. E., Broedl, U. C., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.005081 · Cited by 1,329
Self-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Diabetes Care · doi:10.2337/dc08-9026 · Cited by 881
Renal and retinal effects of enalapril and losartan in type 1 diabetes
Mauer, M., Zinman, B., Gardiner, R., Suissa, S., Sinaiko, A., Strand, T., Drummond, K., Donnelly, S., Goodyer, P., Gubler, M. C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808400 · Cited by 791 · cited 2×
“Unfortunately, blockade of RAAS pathways provides incomplete protection against the development of diabetic complications [6] and dual RAAS blockade strategies may increase the risk of serious adverse effects such as acute kidney injury and hyperkalemia [7,8].”
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
The Diabetes Control and Complications (DCCT) Research Group (1995) · Kidney International · doi:10.1038/ki.1995.236 · Cited by 694
Barnett, A. H., Mithal, A., Manassie, J., Jones, R., Rattunde, H., Woerle, H. J., & Broedl, U. C. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70208-0 · Cited by 574
Self-citationIntensive diabetes therapy and glomerular filtration rate in type 1 diabetes
The DCCT/EDIC Research Group (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1111732 · Cited by 568 · cited 13×
“Intensive glucose lowering therapies exert long lasting renal and cardiovascular protective effects, highlighting the need for improved glucose control in patients with T1D and T2D [30-32].”
Influential&NA;, &. (1993) · Journal of Hypertension · doi:10.1097/00004872-199303000-00012 · Cited by 488
Roden, M., Weng, J., Eilbracht, J., Delafont, B., Kim, G., Woerle, H. J., & Broedl, U. C. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70084-6 · Cited by 450
Self-citationAugmentation index is associated with cardiovascular risk
Nürnberger, J., Keflioglu-Scheiber, A., Opazo Saez, A. M., Wenzel, R. R., Philipp, T., & Schäfers, R. F. (2002) · Journal of Hypertension · doi:10.1097/00004872-200212000-00020 · Cited by 440
Kovacs, C. S., Seshiah, V., Swallow, R., Jones, R., Rattunde, H., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA‐REG PIO™ trial investigators (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12188 · Cited by 387
Self-citationIntensive Glycemic Control in the ACCORD and ADVANCE Trials
Dluhy, R. G., & McMahon, G. T. (2008) · New England Journal of Medicine · doi:10.1056/nejme0804182 · Cited by 378 · cited 1×
“Furthermore, SGLT2 inhibition may avoid some of the most common treatment-related side effects in T2D that have limited the benefits of traditional oral hypoglycemic agents, including significant weight gain, development and worsening of hypertension and severe hypoglycemic events [33,39,57].”
Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes
Häring, H.-U., Merker, L., Seewaldt-Becker, E., Weimer, M., Meinicke, T., Woerle, H. J., Broedl, U. C., & on behalf of the EMPA-REG METSU Trial Investigators (2013) · Diabetes Care · doi:10.2337/dc12-2673 · Cited by 371
Self-citationSkyler, J. S., Bergenstal, R., Bonow, R. O., Buse, J., Deedwania, P., Gale, E. A. M., Howard, B. V., Kirkman, M. S., Kosiborod, M., Reaven, P., et al. (2009) · Circulation · doi:10.1161/circulationaha.108.191305 · Cited by 348
Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2012) · Annals of Medicine · doi:10.3109/07853890.2011.560181 · Cited by 287 · cited 1×
“Previous studies in T2D have suggested that oral hypoglycemic agents such as metformin reduce blood pressure, primarily through improving glycemic control [12-14,43].”
Panchapakesan, U., Pegg, K., Gross, S., Komala, M. G., Mudaliar, H., Forbes, J., Pollock, C., & Mather, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0054442 · Cited by 277
Mackenzie, I. S., McEniery, C. M., Dhakam, Z., Brown, M. J., Cockcroft, J. R., & Wilkinson, I. B. (2009) · Hypertension · doi:10.1161/hypertensionaha.109.133801 · Cited by 221 · cited 1×
“Third, other diuretic agents such as thiazides lower arterial stiffness and these effects are likely in part due to direct effects on vascular smooth muscle relaxation after induction of a negative sodium balance [51,52].”
Hermans, M. M. H., Henry, R., Dekker, J. M., Kooman, J. P., Kostense, P. J., Nijpels, G., Heine, R. J., & Stehouwer, C. D. A. (2007) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006111217 · Cited by 196 · cited 1×
“Our goal was to further clarify the mechanistic basis for the blood pressure lowering effect of empagliflozin, including effects on arterial stiffness and neurohormonal activation measured by heart rate variability, since both of these parameters are associated with systemic blood pressure and correlate with long-term…”
Glucose dynamics and mechanistic implications of SGLT2 inhibitors in animals and humans
List, J. F., & Whaley, J. M. (2011) · Kidney International · doi:10.1038/ki.2010.512 · Cited by 184 · cited 2×
“In addition to having a low risk of hypoglycaemia, this class of oral hypoglycemic agents induces clinically relevant and sustained weight loss and declines in blood pressure in patients with T1D [22,24] and T2D [20,25].”
Microvascular disease: what does the UKPDS tell us about diabetic nephropathy?
Bilous, R. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02496.x · Cited by 174 · cited 13×
“Intensive glucose lowering therapies exert long lasting renal and cardiovascular protective effects, highlighting the need for improved glucose control in patients with T1D and T2D [30-32].”
InfluentialAgarwal, N., Rice, S. P. L., Bolusani, H., Luzio, S. D., Dunseath, G., Ludgate, M., & Rees, D. A. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1985 · Cited by 162 · cited 2×
“Previous studies in T2D have suggested that oral hypoglycemic agents such as metformin reduce blood pressure, primarily through improving glycemic control [12-14,43].”
Renal hyperfiltration related to diabetes mellitus and obesity in human disease
Sasson, A. N. (2012) · World Journal of Diabetes · doi:10.4239/wjd.v3.i1.1 · Cited by 158 · cited 1×
“This is explained in part through effects on activation of the renin angiotensin aldosterone system (RAAS) and sympathetic nervous system (SNS) as well as suppression of nitric oxide [2], leading to macrovascular dysfunction including increased arterial stiffness [3].”
Urinary biomarkers involved in type 2 diabetes: a review
Matheson, A., Willcox, M. D. P., Flanagan, J., & Walsh, B. J. (2010) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.1068 · Cited by 152 · cited 1×
“Due to the strong relationship between inflammation, cardiovascular complications and renal disease, future studies should clarify the ability of SGLT2 inhibitors to suppress inflammation in humans [55].”
Bellien, J., Favre, J., Iacob, M., Gao, J., Thuillez, C., Richard, V., & Joannidès, R. (2010) · Hypertension · doi:10.1161/hypertensionaha.109.142190 · Cited by 143 · cited 1×
“This is explained in part through effects on activation of the renin angiotensin aldosterone system (RAAS) and sympathetic nervous system (SNS) as well as suppression of nitric oxide [2], leading to macrovascular dysfunction including increased arterial stiffness [3].”
ARTERIAL STIFFNESS, ENDOTHELIAL FUNCTION AND NOVEL PHARMACOLOGICAL APPROACHES
Wilkinson, I. B., & McEniery, C. M. (2004) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/j.1440-1681.2004.04074.x · Cited by 120 · cited 2×
“Arterial stiffness is influenced by a variety of factors, including neurohormonal mediators and changes in arterial structure [4].”
Theilade, S., Lajer, M., Persson, F., Joergensen, C., & Rossing, P. (2013) · Diabetes Care · doi:10.2337/dc12-0850 · Cited by 118 · cited 2×
“Our goal was to further clarify the mechanistic basis for the blood pressure lowering effect of empagliflozin, including effects on arterial stiffness and neurohormonal activation measured by heart rate variability, since both of these parameters are associated with systemic blood pressure and correlate with long-term…”
Sodium-Glucose Cotransporter Inhibition Prevents Oxidative Stress in the Kidney of Diabetic Rats
Osorio, H., Coronel, I., Arellano, A., Pacheco, U., Bautista, R., Franco, M., & Escalante, B. (2012) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2012/542042 · Cited by 112 · cited 1×
“For example, in experimental models of diabetes, SGLT2 inhibition reduces oxidative stress and suppresses markers of inflammation and fibrosis, including nuclear factor κβ and collagen IV expression [53,54].”
Prognostic Impact of Aortic Stiffness in High-Risk Type 2 Diabetic Patients
Cardoso, C. R. L., Ferreira, M. T., Leite, N. C., & Salles, G. F. (2013) · Diabetes Care · doi:10.2337/dc13-0506 · Cited by 108 · cited 13×
“Intensive glucose lowering therapies exert long lasting renal and cardiovascular protective effects, highlighting the need for improved glucose control in patients with T1D and T2D [30-32].”
InfluentialSkyler, J. S. (2009) · Diabetes Care · doi:10.2337/dc09-9031 · Cited by 100
Cooper, J. N., Buchanich, J. M., Youk, A. O., Brooks, M. M., Barinas‐Mitchell, E., Conroy, M. B., & Sutton-Tyrrell, K. (2012) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2012.05.022 · Cited by 87 · cited 2×
“First, weight loss independently decreases blood pressure and arterial stiffness [49].”
SGLT2 Inhibitors: A New Emerging Therapeutic Class in the Treatment of Type 2 Diabetes Mellitus
Ghosh, R. K., Ghosh, S. M., Chawla, S., & Jasdanwala, S. A. (2012) · The Journal of Clinical Pharmacology · doi:10.1177/0091270011400604 · Cited by 86
Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes
Gordin, D., Rönnback, M., Forsblom, C. M., Heikkilä, O., Saraheimo, M., & Groop, P. (2007) · Diabetologia · doi:10.1007/s00125-007-0730-0 · Cited by 83 · cited 1×
“Aside from effects of RAAS and SNS activation on vascular function, arterial stiffness increases under the influence of ambient hyperglycaemia and can be improved through tight glycemic control [9-11].”
Intensive Glucose Control and Cardiovascular Outcomes in Type 2 Diabetes
MacIsaac, R. J., & Jerums, G. (2011) · Heart, Lung and Circulation · doi:10.1016/j.hlc.2010.07.013 · Cited by 81 · cited 1×
“Figure 1 Physiological mechanisms implicated in arterial stiffness low lowering strategies also increase the risk of severe hypoglycemic events [15-17] and promote weight gain and sodium retention resulting in higher blood pressure [16-18], thereby mitigating the benefit that can be achieved through tight glycemic con…”
Luippold, G., Klein, T., Mark, M., & Grempler, R. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01569.x · Cited by 76 · cited 1×
“Due to their insulin-independent mechanism of action and as shown in animal models [56], SGLT2 inhibitors have the potential to be used in T1D [22] in addition to T2D [33].”
Forst, T., Michelson, G., Ratter, F., Weber, M. M., Anders, S., Mitry, M., Wilhelm, B., & Pfützner, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03589.x · Cited by 75
Koren, S., Shemesh-Bar, L., Tirosh, A., Peleg, R. K., Berman, S., Hamad, R. A., Vinker, S., Golik, A., & Efrati, S. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2011.0296 · Cited by 69 · cited 1×
“Perhaps as a result of increasing weight, these traditional oral hypoglycemic agents do not improve arterial stiffness parameters and a significant proportion of patients develop hypertension with increasing diabetes duration [45,46].”
Effects of weight loss and insulin reduction on arterial stiffness in the SAVE trial
Hughes, T. M., Althouse, A. D., Niemczyk, N. A., Hawkins, M. S., Kuipers, A. L., & Sutton-Tyrrell, K. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-114 · Cited by 67 · cited 1×
“Second, decreases in daily insulin doses have been correlated with improved arterial compliance in T2D, and a similar interaction may have occurred in our T1D cohort since total daily insulin doses decreased significantly by the end of treatment [22,50].”
Aortic stiffness and cardiovascular risk in type 2 diabetes
Mansour, A. S., Yannoutsos, A., Majahalme, N., Agnoletti, D., Safar, M. E., Ouerdane, S., & Blacher, J. (2013) · Journal of Hypertension · doi:10.1097/hjh.0b013e3283613074 · Cited by 62 · cited 13×
“Intensive glucose lowering therapies exert long lasting renal and cardiovascular protective effects, highlighting the need for improved glucose control in patients with T1D and T2D [30-32].”
InfluentialGlucose variability, blood pressure and arterial stiffness in type 1 diabetes
Gordin, D., Rönnback, M., Forsblom, C. M., Mäkinen, V., Saraheimo, M., & Groop, P. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.01.010 · Cited by 58 · cited 1×
“Aside from effects of RAAS and SNS activation on vascular function, arterial stiffness increases under the influence of ambient hyperglycaemia and can be improved through tight glycemic control [9-11].”
Ficociello, L. H., Perkins, B. A., Silva, K. H., Finkelstein, D. M., Ignatowska-Switalska, H., Gaciong, Z., Cupples, L. A., Aschengrau, A., Warram, J. H., & Krolewski, A. S. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03691106 · Cited by 54 · cited 2×
“Unfortunately, blockade of RAAS pathways provides incomplete protection against the development of diabetic complications [6] and dual RAAS blockade strategies may increase the risk of serious adverse effects such as acute kidney injury and hyperkalemia [7,8].”
Self-citationMudaliar, S., Armstrong, D. A., Mavian, A. A., O’Connor-Semmes, R., Mydlow, P. K., Ye, J., Hussey, E. K., Nunez, D. J., Henry, R. R., & Dobbins, R. L. (2012) · Diabetes Care · doi:10.2337/dc12-0508 · Cited by 53 · cited 1×
“Since these agents lower blood glucose through insulin-independent increases in urinary glucose excretion, SGLT2 inhibition has also been used in T1D patients, and improves glycemic control [22,23].”
Cherney, D. Z. I., Scholey, J. W., Jiang, S., Har, R., Lai, V., Sochett, E. B., & Reich, H. N. (2012) · Diabetes Care · doi:10.2337/dc12-0773 · Cited by 53 · cited 1×
“The use of the SphygmoCor device to assess arterial stiffness parameters has been previously published by our group [28].”
Self-citationKim, S. G., Ryu, O. H., Kim, H. Y., Lee, K. W., Seo, J. A., Kim, N. H., Choi, K. M., Lee, J., Baik, S. H., & Cho, Y. (2006) · European Journal of Endocrinology · doi:10.1530/eje.1.02100 · Cited by 50 · cited 2×
“Previous studies in T2D have suggested that oral hypoglycemic agents such as metformin reduce blood pressure, primarily through improving glycemic control [12-14,43].”
Kiyici, S. K., Ersoy, C., Kaderlï, A. A., Fazlıoğlu, M., Budak, F., Duran, C., Gül, Ö. Ö., Sığırlı, D., Baran, İ., Tuncel, E., et al. (2009) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.07.004 · Cited by 46 · cited 2×
“Previous studies in T2D have suggested that oral hypoglycemic agents such as metformin reduce blood pressure, primarily through improving glycemic control [12-14,43].”
Cherney, D. Z. I., Scholey, J. W., Nasrallah, R., Dekker, M. G., Slorach, C., Bradley, T. J., Hébert, R. L., Sochett, E. B., & Miller, J. A. (2008) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00574.2007 · Cited by 44 · cited 2×
“Urinary albumin concentration was determined by immunoturbidimetry and HbA1C was measured by high-performance liquid chromatography [27].”
Self-citationRing, A., Brand, T., Macha, S., Breithaupt-Groegler, K., Simons, G., Walter, B., Woerle, H. J., & Broedl, U. C. (2013) · Cardiovascular Diabetology · doi:10.1186/1475-2840-12-70 · Cited by 43
Self-citationvan Ittersum, F. J., Schram, M. T., Spek, J. J., Bortel, L. M. V., Elte, J. W. F., Biemond, P., Staessen, J. A., Donker, A. J. M., & Stehouwer, C. D. A. (2004) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001751 · Cited by 41 · cited 2×
“Our goal was to further clarify the mechanistic basis for the blood pressure lowering effect of empagliflozin, including effects on arterial stiffness and neurohormonal activation measured by heart rate variability, since both of these parameters are associated with systemic blood pressure and correlate with long-term…”
Manolis, A. J., Iraklianou, S., Pittaras, A. E., Zairis, M. N., Tsioufis, K. P., Psaltiras, G., PSOMALI, D., Foussas, S. G., Gavras, H. P., & Gavras, H. P. (2005) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.014 · Cited by 39
Rosenstock, J., Jelaska, A., Wang, F., Kim, G., Broedl, U. C., Woerle, H. J., & BAJAJ, H. S. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.08.093 · Cited by 38
Self-citationKöenig, W., BINNER, L., Gabrielsen, F. G., Sund, M., Rosenthal, J. H., & Hombach, V. (1991) · Journal of Cardiovascular Pharmacology · doi:10.1097/00005344-199109000-00007 · Cited by 28 · cited 1×
“expected effects of a thiazide diuretic [24,47].”
Shestakova, M. V., Jarek-Martynowa, I. R., Ivanishina, N. S., Kukharenko, S. S., Ядрихинская, М. Н., Александров, А. А., & Dedov, I. I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.009 · Cited by 28
Impact of Glycemic Treatment Choices on Cardiovascular Complications in Type 2 Diabetes
Weiss, I. A., Valiquette, G., & Schwarcz, M. (2009) · Cardiology in Review · doi:10.1097/crd.0b013e3181a7b34c · Cited by 28 · cited 13×
“Intensive glucose lowering therapies exert long lasting renal and cardiovascular protective effects, highlighting the need for improved glucose control in patients with T1D and T2D [30-32].”
InfluentialSGLT2 Inhibitors to Control Glycemia in Type 2 Diabetes Mellitus: A New Approach to an Old Problem
Jabbour, S. A. (2014) · Postgraduate Medicine · doi:10.3810/pgm.2014.01.2731 · Cited by 28 · cited 2×
“Furthermore, SGLT2 inhibition may avoid some of the most common treatment-related side effects in T2D that have limited the benefits of traditional oral hypoglycemic agents, including significant weight gain, development and worsening of hypertension and severe hypoglycemic events [33,39,57].”
Villafaña, S., Huang, F., & Hong, E. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.10.055 · Cited by 26 · cited 6×
“This is explained in part through effects on activation of the renin angiotensin aldosterone system (RAAS) and sympathetic nervous system (SNS) as well as suppression of nitric oxide [2], leading to macrovascular dysfunction including increased arterial stiffness [3].”
InfluentialAgarwal, N., Rice, S., Bolusani, H., Luzio, S. D., Dunseath, G. J., Ludgate, M. E., & Rees, A. (2010) · Obstetrical & Gynecological Survey · doi:10.1097/ogx.0b013e3181e5a167 · Cited by 12
Cherney, D. Z. I., LAI, V. S., Miller, J. A., Scholey, J. W., & Reich, H. N. (2010) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfq564 · Cited by 10 · cited 1×
“Plasma noradrenalin and adrenaline concentrations were obtained on each of the study days according to standard, previously described methods [29].”
Self-citationRosenstock, J., Jelaska, A., Kim, G., Broedl, U., & Woerle, H. J. (2014) · Diabetologie und Stoffwechsel · doi:10.1055/s-0034-1374994 · Cited by 7
Self-citationIncreased vascular compliance/decreased cardiovascular risk: what the studies tell us.
Frishman, W. H. (2000) · PubMed · Cited by 6
Cardiac cellular actions of hydrochlorothiazide
Galán-Martínez, L., Ferrer, T., Artiles, A., Talavera, K., Salinas-Stefanon, E. M., Orta, G., García-Barreto, D., & Álvarez, J. L. (2001) · Fundamental and Clinical Pharmacology · doi:10.1046/j.1472-8206.2001.00009.x · Cited by 6 · cited 1×
“Third, other diuretic agents such as thiazides lower arterial stiffness and these effects are likely in part due to direct effects on vascular smooth muscle relaxation after induction of a negative sodium balance [51,52].”
Research works printed but not linked: 1
- Perkins BA Cherney DZI Partridge H Soleymanlou N Tschirhart H Zinman B Fagan N Kaspers S Woerle HJ Broedl UC The sodium glucose co-transporter-2 (SGLT2) inhibitor empagliflozin improves glycemic control in patients with type 1 diabetes: a single-arm clinical trial Diabetes Care 2013 in press
Cited by
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Self-citation2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Heerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationMechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Metadata
- Authors
- Cherney, D. Z., Perkins, B. A., Soleymanlou, N., Har, R., Fagan, N., Johansen, O., Woerle, H.-J., von Eynatten, M., & Broedl, U. C.
- Affiliations
- University Health Network (CA)
- Boehringer Ingelheim (Canada) (CA)
- Boehringer Ingelheim (United States) (US)
- Boehringer Ingelheim (Germany) (DE)
- Corresponding author
- Cherney, David ZI
- Venue
- Cardiovascular Diabetology
- Published
- 2014
- Volume
- 13
- Issue
- 1
- Pages
- 28
- ISSN
- 1475-2840 (ISSN-L)
- PMC
- PMC3915232
- OpenAlex
- W2148513135
- Cited by
- 470
- References
- 63
- Citations by year
- 2026: 11 · 2025: 19 · 2024: 27 · 2023: 30 · 2022: 40 · 2021: 52 · 2020: 55 · 2019: 46 · 2018: 49 · 2017: 46 · 2016: 49 · 2015: 33 · 2014: 12
- FWCI
- 32.07
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Cardiovascular Diabetology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- TSpace (University of Toronto) (submittedVersion)
- Funders
- American Society of Nephrology
- Heart and Stroke Foundation of Canada
- Canadian Diabetes Association
- Kidney Foundation of Canada
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Health and Disease Prevention
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Keywords
- empagliflozin, type 1 diabetes, arterial stiffness, heart rate variability, SGLT2 inhibitors, hyperglycemia, pulse wave velocity, blood pressure, sympathetic activity, norepinephrine, epinephrine, hypertension, cardiovascular complications, neurohormonal activation, augmentation index
- MeSH terms
- Adult, Benzhydryl Compounds, Blood Pressure, Diabetes Mellitus, Type 1, Female, Glucosides, Heart Rate, Humans, Male, Prospective Studies, Cohort Studies, Treatment Outcome, Young Adult, Vascular Stiffness
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.